<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.journal-inflammation.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Inflammation - Most accessed articles</title>
        <link>http://www.journal-inflammation.com</link>
        <description>The most accessed research articles published by Journal of Inflammation</description>
        <dc:date>2011-10-13T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/8/1/9" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/8/1/21" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/8/1/22" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/8/1/27" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/4/1/15" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/2/1/8" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/1" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/7/1/6" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/5/1/9" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.journal-inflammation.com/content/8/1/9">
        <title>Innate immunity and monocyte-macrophage activation in atherosclerosis</title>
        <description>Innate inflammation is a hallmark of both experimental and human atherosclerosis. The predominant innate immune cell in the atherosclerotic plaque is the monocyte-macrophage. The behaviour of this cell type within the plaque is heterogeneous and depends on the recruitment of diverse monocyte subsets. Furthermore, the plaque microenvironment offers polarisation and activation signals which impact on phenotype. Microenvironmental signals are sensed through pattern recognition receptors, including toll-like and NOD-like receptors thus dictating macrophage behaviour and outcome in atherosclerosis. Recently cholesterol crystals and modified lipoproteins have been recognised as able to directly engage these pattern recognition receptors. The convergent role of such pathways in terms of macrophage activation is discussed in this review.</description>
        <link>http://www.journal-inflammation.com/content/8/1/9</link>
                <dc:creator>Joseph Shalhoub</dc:creator>
                <dc:creator>Mika Falck-Hansen</dc:creator>
                <dc:creator>Alun Davies</dc:creator>
                <dc:creator>Claudia Monaco</dc:creator>
                <dc:source>Journal of Inflammation 2011, null:9</dc:source>
        <dc:date>2011-04-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-8-9</dc:identifier>
                                <prism:require>/content/figures/1476-9255-8-9-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2011-04-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/8/1/21">
        <title>Tyrosine Kinases in Rheumatoid Arthritis</title>
        <description>Rheumatoid arthritis (RA) is an inflammatory, polyarticular joint disease. A number of cellular responses are involved in the pathogenesis of rheumatoid arthritis, including activation of inflammatory cells and cytokine expression. The cellular responses involved in each of these processes depends on the specific signaling pathways that are activated; many of which include protein tyrosine kinases. These pathways include the mitogen-activated protein kinase pathway, Janus kinases/signal transducers and activators transcription pathway, spleen tyrosine kinase signaling, and the nuclear factor &#954;-light-chain-enhancer of activated B cells pathway. Many drugs are in development to target tyrosine kinases for the treatment of RA. Based on the number of recently published studies, this manuscript reviews the role of tyrosine kinases in the pathogenesis of RA and the potential role of kinase inhibitors as new therapeutic strategies of RA.</description>
        <link>http://www.journal-inflammation.com/content/8/1/21</link>
                <dc:creator>Hiroshi Okamoto</dc:creator>
                <dc:creator>Akiko Kobayashi</dc:creator>
                <dc:source>Journal of Inflammation 2011, null:21</dc:source>
        <dc:date>2011-08-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-8-21</dc:identifier>
                                <prism:require>/content/figures/1476-9255-8-21-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2011-08-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/8/1/22">
        <title>Role of IL-33 in inflammation and disease</title>
        <description>Interleukin (IL)-33 is a new member of the IL-1 superfamily of cytokines that is expressed by mainly stromal cells, such as epithelial and endothelial cells, and its expression is upregulated following pro-inflammatory stimulation. IL-33 can function both as a traditional cytokine and as a nuclear factor regulating gene transcription. It is thought to function as an &apos;alarmin&apos; released following cell necrosis to alerting the immune system to tissue damage or stress. It mediates its biological effects via interaction with the receptors ST2 (IL-1RL1) and IL-1 receptor accessory protein (IL-1RAcP), both of which are widely expressed, particularly by innate immune cells and T helper 2 (Th2) cells. IL-33 strongly induces Th2 cytokine production from these cells and can promote the pathogenesis of Th2-related disease such as asthma, atopic dermatitis and anaphylaxis. However, IL-33 has shown various protective effects in cardiovascular diseases such as atherosclerosis, obesity, type 2 diabetes and cardiac remodeling. Thus, the effects of IL-33 are either pro- or anti-inflammatory depending on the disease and the model. In this review the role of IL-33 in the inflammation of several disease pathologies will be discussed, with particular emphasis on recent advances.</description>
        <link>http://www.journal-inflammation.com/content/8/1/22</link>
                <dc:creator>Ashley Miller</dc:creator>
                <dc:source>Journal of Inflammation 2011, null:22</dc:source>
        <dc:date>2011-08-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-8-22</dc:identifier>
                                <prism:require>/content/figures/1476-9255-8-22-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2011-08-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/8/1/27">
        <title>Antioxidant and potential anti-inflammatory activity of extracts and formulations of white tea, rose, and witch hazel on primary human dermal fibroblast cells </title>
        <description>Background:
Numerous reports have identified therapeutic roles for plants and their extracts and constituents. The aim of this study was to assess the efficacies of three plant extracts for their potential antioxidant and anti-inflammatory activity in primary human skin fibroblasts.
Methods:
Aqueous extracts and formulations of white tea, witch hazel and rose were subjected to assays to measure anti-collagenase, anti-elastase, trolox equivalent and catalase activities. Skin fibroblast cells were employed to determine the effect of each extract/formulation on IL-8 release induced by the addition of hydrogen peroxide. Microscopic examination along with Neutral Red viability testing was employed to ascertain the effects of hydrogen peroxide directly on cell viability.
Results:
Considerable anti-collagenase, anti-elastase, and antioxidant activities were measured for all extracts apart from the witch hazel distillate which showed no activity in the collagenase assay or in the trolox equivalence assay. All of the extracts and products tested elicited a significant decrease in the amount of IL-8 produced by fibroblast cells compared to the control (p &lt; 0.05). None of the test samples exhibited catalase activity or had a significant effect on the spontaneous secretion of IL-8 in the control cells which was further corroborated with the microscopy results and the Neutral Red viability test.
Conclusions:
These data show that the extracts and products tested have a protective effect on fibroblast cells against hydrogen peroxide induced damage. This approach provides a potential method to evaluate the claims made for plant extracts and the products in which these extracts are found.</description>
        <link>http://www.journal-inflammation.com/content/8/1/27</link>
                <dc:creator>Tamsyn Thring</dc:creator>
                <dc:creator>Pauline Hili</dc:creator>
                <dc:creator>Declan Naughton</dc:creator>
                <dc:source>Journal of Inflammation 2011, null:27</dc:source>
        <dc:date>2011-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-8-27</dc:identifier>
                            <dc:title>Plant extracts exhibit anti-inflammatory properties</dc:title>
                            <dc:description>Extracts of white tea, rose and witch hazel have been shown to have anti-inflammatory effects on fibroblasts, cells crucial for wound healing, providing a method to evaluate the benefits of plant extracts in therapeutics.</dc:description>
                <prism:require>/content/figures/1476-9255-8-27-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2011-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/4/1/15">
        <title>Free radical scavenging activity and lipoxygenase inhibition of Mahonia aquifolium extract and isoquinoline alkaloids</title>
        <description>Roots and stem-bark of Mahonia aquifolium (Oregon grape) (Berberidaceae) are effectively used in the treatment of skin inflammatory conditions.In the present study, the effect of Mahonia aquifolium crude extract and its two representative alkaloid fractions containing protoberberine and bisbenzylisoquinoline (BBIQ) alkaloids on activity of 12-lipoxygenase (12-LOX), was studied. The reactivity with 1,1-diphenyl-2-picryl-hydrazyl (DPPH), a free stable radical, was evaluated to elucidate the rate of possible lipid-derived radical scavenging in the mechanism of the enzyme inhibition.The results indicate that although the direct radical scavenging mechanism cannot be ruled out in the lipoxygenase inhibition by Mahonia aquifolium and its constituents, other mechanisms based on specific interaction between enzyme and alkaloids could play the critical role in the lipoxygenase inhibition rather than non-specific reactivity with free radicals.</description>
        <link>http://www.journal-inflammation.com/content/4/1/15</link>
                <dc:creator>Lucia Rackova</dc:creator>
                <dc:creator>Marek Oblozinsky</dc:creator>
                <dc:creator>Daniela Kostalova</dc:creator>
                <dc:creator>Viktor Kettmann</dc:creator>
                <dc:creator>Lydia Bezakova</dc:creator>
                <dc:source>Journal of Inflammation 2007, null:15</dc:source>
        <dc:date>2007-07-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-4-15</dc:identifier>
                                <prism:require>/content/figures/1476-9255-4-15-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2007-07-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/2/1/8">
        <title>Mesenchymal stem cells avoid allogeneic rejection</title>
        <description>Adult bone marrow derived mesenchymal stem cells offer the potential to open a new frontier in medicine. Regenerative medicine aims to replace effete cells in a broad range of conditions associated with damaged cartilage, bone, muscle, tendon and ligament. However the normal process of immune rejection of mismatched allogeneic tissue would appear to prevent the realisation of such ambitions. In fact mesenchymal stem cells avoid allogeneic rejection in humans and in animal models. These finding are supported by in vitro co-culture studies. Three broad mechanisms contribute to this effect. Firstly, mesenchymal stem cells are hypoimmunogenic, often lacking MHC-II and costimulatory molecule expression. Secondly, these stem cells prevent T cell responses indirectly through modulation of dendritic cells and directly by disrupting NK as well as CD8+ and CD4+ T cell function. Thirdly, mesenchymal stem cells induce a suppressive local microenvironment through the production of prostaglandins and interleukin-10 as well as by the expression of indoleamine 2,3,-dioxygenase, which depletes the local milieu of tryptophan. Comparison is made to maternal tolerance of the fetal allograft, and contrasted with the immune evasion mechanisms of tumor cells. Mesenchymal stem cells are a highly regulated self-renewing population of cells with potent mechanisms to avoid allogeneic rejection.</description>
        <link>http://www.journal-inflammation.com/content/2/1/8</link>
                <dc:creator>Jennifer Ryan</dc:creator>
                <dc:creator>Frank Barry</dc:creator>
                <dc:creator>J. Murphy</dc:creator>
                <dc:creator>Bernard Mahon</dc:creator>
                <dc:source>Journal of Inflammation 2005, null:8</dc:source>
        <dc:date>2005-07-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-2-8</dc:identifier>
                                <prism:require>/content/figures/1476-9255-2-8-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2005-07-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/8/1/4">
        <title>Low Level Bacterial Endotoxin Activates Two Distinct Signaling Pathways in Human Peripheral Blood Mononuclear Cells</title>
        <description>Background:
Bacterial endotoxin, long recognized as a potent pro-inflammatory mediator in acute infectious processes, has more recently been identified as a risk factor for atherosclerosis and other cardiovascular diseases. When endotoxin enters the bloodstream, one of the first cells activated is the circulating monocyte, which exhibits a wide range of pro-inflammatory responses.
Methods:
We studied the effect of low doses of E. coli LPS on IL-8 release and superoxide formation by freshly isolated human peripheral blood mononuclear cells (PBMC).
Results:
IL-8 release was consistently detectable at 10 pg/ml of endotoxin, reaching a maximum at 1 ng/ml, and was exclusively produced by monocytes; the lymphocytes neither produced IL-8, nor affected monocyte IL-8 release. Superoxide production was detectable at 30 pg/ml of endotoxin, reaching a maximum at 3 ng/ml. Peak respiratory burst activity was seen at 15-20 min, and superoxide levels returned to baseline by 1 h. IL-8 release was dependent on both membrane-associated CD14 (mCD14) and Toll-like receptor 4 (TLR4. Superoxide production was dependent on the presence of LBP, but was not significantly affected by a blocking antibody to TLR4. Moreover, treatment with lovastatin inhibited LPS-dependent IL-8 release and superoxide production.
Conclusions:
These findings suggest that IL-8 release and the respiratory burst are regulated by distinct endotoxin-dependent signaling pathways in PBMC in low level of endotoxin exposure. Selectively modulating these pathways could lead to new approaches to treat chronic inflammatory diseases, such as atherosclerosis, while preserving the capacity of monocytes to respond to acute bacterial infections.</description>
        <link>http://www.journal-inflammation.com/content/8/1/4</link>
                <dc:creator>Andra Blomkalns</dc:creator>
                <dc:creator>Lynn Stoll</dc:creator>
                <dc:creator>Wassim Shaheen</dc:creator>
                <dc:creator>Sara Romig-Martin</dc:creator>
                <dc:creator>Eric Dickson</dc:creator>
                <dc:creator>Neal Weintraub</dc:creator>
                <dc:creator>Gerene Denning</dc:creator>
                <dc:source>Journal of Inflammation 2011, null:4</dc:source>
        <dc:date>2011-02-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-8-4</dc:identifier>
                                <prism:require>/content/figures/1476-9255-8-4-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2011-02-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/1">
        <title>Signaling pathways involved in LPS induced TNFalpha production in human adipocytes </title>
        <description>Background:
The development of obesity has been linked to an inflammatory process, and the role of adipose tissue in the secretion of pro-inflammatory molecules such as IL-6 or TNFalpha has now been largely confirmed. Although TNFalpha secretion by adipose cells is probably induced, most notably by TLR ligands, the activation and secretion pathways of this cytokine are not yet entirely understood. Moreover, given that macrophagic infiltration is a characteristic of obesity, it is difficult to clearly establish the level of involvement of the different cellular types present within the adipose tissue during inflammation.
Methods:
Primary cultures of human adipocytes and human peripheral blood mononuclear cells were used. Cells were treated with a pathogen-associated molecular pattern: LPS, with and without several kinase inhibitors. Western blot for p38 MAP Kinase was performed on cell lysates. TNFalpha mRNA was detected in cells by RT-PCR and TNFalpha protein was detected in supernatants by ELISA assays.
Results:
We show for the first time that the production of TNFalpha in mature human adipocytes is mainly dependent upon two pathways: NFkappaB and p38 MAP Kinase. Moreover, we demonstrate that the PI3Kinase pathway is clearly involved in the first step of the LPS-pathway. Lastly, we show that adipocytes are able to secrete a large amount of TNFalpha compared to macrophages.
Conclusion:
This study clearly demonstrates that the LPS induced activation pathway is an integral part of the inflammatory process linked to obesity, and that adipocytes are responsible for most of the secreted TNFalpha in inflamed adipose tissue, through TLR4 activation.</description>
        <link>http://www.journal-inflammation.com/content/7/1/1</link>
                <dc:creator>Laurence Hoareau</dc:creator>
                <dc:creator>Karima Bencharif</dc:creator>
                <dc:creator>Philippe Rondeau</dc:creator>
                <dc:creator>Ravi Murumalla</dc:creator>
                <dc:creator>Palaniyandi Ravanan</dc:creator>
                <dc:creator>Frank Tallet</dc:creator>
                <dc:creator>Pierre Delarue</dc:creator>
                <dc:creator>Maya Cesari</dc:creator>
                <dc:creator>Regis Roche</dc:creator>
                <dc:creator>Franck Festy</dc:creator>
                <dc:source>Journal of Inflammation 2010, null:1</dc:source>
        <dc:date>2010-01-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-1</dc:identifier>
                                <prism:require>/content/figures/1476-9255-7-1-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/7/1/6">
        <title>Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock</title>
        <description>Background:
Lactate clearance, a surrogate for the magnitude and duration of global tissue hypoxia, is used diagnostically, therapeutically and prognostically. This study examined the association of early lactate clearance with selected inflammatory, coagulation, apoptosis response biomarkers and organ dysfunction scores in severe sepsis and septic shock.
Methods:
Measurements of serum arterial lactate, biomarkers (interleukin-1 receptor antagonist, interleukin-6, interleukin-8, interleukin-10, tumor necrosis factor-alpha, intercellular adhesion molecule-1, high mobility group box-1, D-Dimer and caspase-3), and organ dysfunction scores (Acute Physiology and Chronic Health Evaluation II, Simplified Acute Physiology Score II, Multiple Organ Dysfunction Score, and Sequential Organ Failure Assessment) were obtained in conjunction with a prospective, randomized study examining early goal-directed therapy in severe sepsis and septic shock patients presenting to the emergency department (ED). Lactate clearance was defined as the percent change in lactate levels after six hours from a baseline measurement in the ED.
Results:
Two-hundred and twenty patients, age 65.0 +/- 17.1 years, were examined, with an overall lactate clearance of 35.5 +/- 43.1% and in-hospital mortality rate of 35.0%. Patients were divided into four quartiles of lactate clearance, -24.3 +/- 42.3, 30.1 +/- 7.5, 53.4 +/- 6.6, and 75.1 +/- 7.1%, respectively (p &lt; 0.01). The mean levels of all biomarkers and organ dysfunction scores over 72 hours were significantly lower with higher lactate clearance quartiles (p &lt; 0.01). There was a significant decreased in-hospital, 28-day, and 60-day mortality in the higher lactate clearance quartiles (p &lt; 0.01).
Conclusions:
Early lactate clearance as a surrogate for the resolution of global tissue hypoxia is significantly associated with decreased levels of biomarkers, improvement in organ dysfunction and outcome in severe sepsis and septic shock.</description>
        <link>http://www.journal-inflammation.com/content/7/1/6</link>
                <dc:creator>H. Bryant Nguyen</dc:creator>
                <dc:creator>Manisha Loomba</dc:creator>
                <dc:creator>James Yang</dc:creator>
                <dc:creator>Gordon Jacobsen</dc:creator>
                <dc:creator>Kant Shah</dc:creator>
                <dc:creator>Ronny Otero</dc:creator>
                <dc:creator>Arturo Suarez</dc:creator>
                <dc:creator>Hemal Parekh</dc:creator>
                <dc:creator>Anja Jaehne</dc:creator>
                <dc:creator>Emanuel Rivers</dc:creator>
                <dc:source>Journal of Inflammation 2010, null:6</dc:source>
        <dc:date>2010-01-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-7-6</dc:identifier>
                                <prism:require>/content/figures/1476-9255-7-6-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-01-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/5/1/9">
        <title>Bioavailable constituents / metabolites of pomegranate (Punica granatum L) preferentially inhibit COX2 activity ex vivo and IL-1beta-induced PGE2 production in human chondrocytes in vitro</title>
        <description>Several recent studies have documented that supplementation with pomegranate fruit extract inhibits inflammatory symptoms in vivo. However, the molecular basis of the observed effects has not been fully revealed. Although previous studies have documented the inhibition of nitric oxide and cyclooxygenase (COX) activity in vitro by plant and fruit extracts added directly into the culture medium but whether concentrations of bioactive compounds sufficient enough to exert such inhibitory effects in vivo can be achieved through oral consumption has not been reported. In the present study we determined the effect of rabbit plasma obtained after ingestion of a polyphenol rich extract of pomegranate fruit (PFE) on COX enzyme activity ex vivo and the IL-1&#946;-induced production of NO and PGE2 in chondrocytes in vitro. Plasma samples collected before and 2 hr after supplementation with PFE were tested. Plasma samples collected after oral ingestion of PFE were found to inhibit the IL-1&#946;-induced PGE2 and NO production in chondrocytes. These same plasma samples also inhibited both COX-1 and COX-2 enzyme activity ex vivo but the effect was more pronounced on the enzyme activity of COX-2 enzyme. Taken together these results provide additional evidence of the bioavailability and bioactivity of compounds present in pomegranate fruit after oral ingestion. Furthermore, these studies suggest that PFE-derived bioavailable compounds may exert an anti-inflammatory effect by inhibiting the inflammatory cytokine-induced production of PGE2 and NO in vivo.</description>
        <link>http://www.journal-inflammation.com/content/5/1/9</link>
                <dc:creator>Meenakshi Shukla</dc:creator>
                <dc:creator>Kalpana Gupta</dc:creator>
                <dc:creator>Zafar Rasheed</dc:creator>
                <dc:creator>Khursheed Khan</dc:creator>
                <dc:creator>Tariq Haqqi</dc:creator>
                <dc:source>Journal of Inflammation 2008, null:9</dc:source>
        <dc:date>2008-06-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-5-9</dc:identifier>
                            <dc:title>A pomegranate a day&amp;#8230; </dc:title>
                            <dc:description>Oral pomegranate juice extracts are both bioavailable and bioactive, inhibit cyclo-oxygenase enzymes and may have anti-inflammatory properties through mediation of cytokine-induced prostaglandin and nitric oxide production.</dc:description>
                <prism:require>/content/figures/1476-9255-5-9-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2008-06-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

